Numerous aspects of lung cancer research are dependent on pathology diagnostic expertise as well as numerous pathology-related services. The Pathology Core Resource is dedicated to providing pathology support services for investigators of the UCLA Lung SPORE program. These services include 1) human and veterinary pathology consultation, 2) procurement of remnant tissue samples, 3) histology, 4) immunohistochemistry and in situ hybridization, 5) laser-capture microdissection, 5) electron microscopy, 6) morphometry and imaging, 7) tissue arrays, and 8) molecular pathology. Notably, the Pathology Core Resource is currently functional and highly successful. Services and technologies provided by the Pathology Core Resource are critically important for understanding the pathogenesis of diseases such as lung cancer. As such, all projects presented in this grant propose to utilize one or more components of this shared resource. In addition to the scientific advantages that this core affords, this resource is cost-effective as the cost for individual researchers to perform such activities on their own would be prohibitively expensive. The Pathology Core Resource is directed by a team of faculty members with expertise in the specific pathology services mentioned as well as experience in tumor biology research In addition, the technical staff is highly skilled. Significantly, all members of the Pathology Core Resource are committed to the success of the UCLA Lung SPORE program. Thus, our Aim there is to supplement the funding of this facility and therefore; i) enable continued expansion and optimization of services; and ii) allow a focused efforts to provide services specifically dedicated to promoting lung cancer research at UCLA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA090388-01
Application #
6465104
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-06-01
Project End
2005-12-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lee, Jay M; Lee, Mi-Heon; Garon, Edward et al. (2017) Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res 23:4556-4568
Kawakita, Daisuke; Lee, Yuan-Chin Amy; Turati, Federica et al. (2017) Dietary fiber intake and head and neck cancer risk: A pooled analysis in the International Head and Neck Cancer Epidemiology consortium. Int J Cancer 141:1811-1821
Boffetta, Paolo; Hayes, Richard B; Sartori, Samantha et al. (2016) Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev 25:344-8
Miles, Fayth L; Chang, Shen-Chih; Morgenstern, Hal et al. (2016) Association of sugary beverages with survival among patients with cancers of the upper aerodigestive tract. Cancer Causes Control 27:1293-1300
Wyss, Annah B; Hashibe, Mia; Lee, Yuan-Chin Amy et al. (2016) Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. Am J Epidemiol 184:703-716
Leoncini, Emanuele; Edefonti, Valeria; Hashibe, Mia et al. (2016) Carotenoid intake and head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Eur J Epidemiol 31:369-83
Hashim, D; Sartori, S; Brennan, P et al. (2016) The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol 27:1619-25
Myneni, Ajay A; Chang, Shen-Chih; Niu, Rungui et al. (2016) Raw Garlic Consumption and Lung Cancer in a Chinese Population. Cancer Epidemiol Biomarkers Prev 25:624-33
Alavi, Mohammed; Mah, Vei; Maresh, Erin L et al. (2015) High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 15:655
Reckamp, Karen L; Koczywas, Marianna; Cristea, Mihaela C et al. (2015) Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer 121:3298-306

Showing the most recent 10 out of 201 publications